Abbott Laboratories vs Johnson & Johnson
ABT and JNJ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABT and JNJ compare
Johnson & Johnson is the larger company, worth 3.6 times as much as Abbott Laboratories ($658B against $184B).
On earnings, Johnson & Johnson is cheaper: it trades at 31.7× trailing earnings, against 34.1× for Abbott Laboratories.
Abbott Laboratories grew revenue faster over the last twelve months (8.1% versus 8.1% for Johnson & Johnson).
Johnson & Johnson keeps more of each dollar of sales as profit, with a net margin of 21.5% compared with 11.6% at Abbott Laboratories.
Both pay dividends: Abbott Laboratories yields 2.4% and Johnson & Johnson 1.9%.
Abbott Laboratories scores higher on the StockData Score (14 against 12 for Johnson & Johnson), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABT | JNJ |
|---|---|---|
| Size and price | ||
| Market cap | $184B | $658B |
| Share price | $106.20 | $273.20 |
| Change, 1 year | −14.7% | 46.4% |
| Change, 5 years | −14.6% | 67.2% |
| Beta (5Y) | 0.47 | 0.20 |
| Employees | 115K | 138K |
| StockData Score | ||
| Total score | 14 (better) | 12 |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 | 3 |
| Performance score | 3 | 4 (better) |
| Health score | 4 (better) | 3 |
| Dividend score | 3 (better) | 2 |
| Valuation | ||
| P/E | 34.1× | 31.7× (better) |
| P/S | 3.9× (better) | 6.7× |
| P/B | 3.6× (better) | 7.7× |
| EV/EBITDA | 28.8× | 20.2× (better) |
| P/FCF | 23.5× (better) | 29.6× |
| PEG | – | 1.77 |
| FCF yield | 4.3% (better) | 3.4% |
| Fair value | $78.11 | $190.51 |
| Margin of safety | −36.0% (better) | −43.4% |
| Growth | ||
| Revenue growth (TTM) | 8.1% (better) | 8.1% |
| Revenue growth, 5Y average | 5.1% (better) | 2.7% |
| Net income growth (TTM) | −61.2% | −7.2% (better) |
| EPS growth (TTM) | −61.1% | −7.8% (better) |
| EPS growth, 5Y average | 8.3% | 14.9% (better) |
| Profitability | ||
| Gross margin | 56.6% | 67.9% (better) |
| Operating margin | 15.8% | – |
| Net margin | 11.6% | 21.5% (better) |
| FCF margin | 16.8% | 22.7% (better) |
| Return on equity | 10.7% | 25.7% (better) |
| Return on invested capital | 7.9% | – |
| Financial health | ||
| Debt / equity | 0.64 | 0.58 (better) |
| Net debt / EBITDA | 3.68 | 0.83 (better) |
| Interest coverage | 9.6× | – |
| Current ratio | 1.38 (better) | 1.09 |
| Altman Z-score | 3.28 | 5.11 (better) |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 2.4% (better) | 1.9% |
| Payout ratio | 78.5% | – |
| Years of dividend growth | 3 | 16 (better) |
| Dividend growth, 5Y average | – | 5.2% |
| Buyback yield | 1.00% | 1.2% (better) |
| Shareholder yield | 3.4% (better) | 3.2% |
| Ownership | ||
| Held by institutions | 79.8% | 74.7% |
| Held by insiders | 0.50% | 0.04% |
| Insider net buying, 12 months | −$43.1M (better) | −$150M |
| Superinvestors holding | 2 | 6 (better) |
| Short interest, % of float | 0.79% | 0.92% |
Go deeper
- ABT stock overview
- ABT income statement
- ABT valuation and score
- JNJ stock overview
- JNJ income statement
- JNJ valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.